Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

2 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NWW0fXo1TnWwY4Tpc44hSXO|YYm= MlfpNE4yNTNyIN88US=> NHjvSoI1QCCq M{PTZYlv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt MnHWNlY2OTNzN{K=
H460 M1W0UGZ2dmO2aX;uJGF{e2G7 NEP0dpExNjFvM{Cg{txO M1XQfVQ5KGh? NXjDNYtLcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? MXyyOlUyOzF5Mh?=
HKESC-2 MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHS[24zOMLizszN M{LzOVQ5yqCqwrC= NFzyOVF{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MYmyOlQ4PDZ7Mx?=
CaES-17 M1LwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmyNOKh|ryP NHO1bnU1QMLiaNMg MkPid4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh MnWzNlY1PzR4OUO=
HKESC-2 M2PvcGFxd3C2b4Ppd{BCe3OjeR?= M1HkNlIxyqEQvF2= NXX4bWN{PDkEoHlCpC=> MXry[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz NVL1V3NJOjZ2N{S2PVM>
CaES-17 M33YdmFxd3C2b4Ppd{BCe3OjeR?= NULxOGx5OjEEoN88US=> NH3UWXU1QMLiaNMg Ml\jdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MUeyOlQ4PDZ7Mx?=
A549 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\obVUuOTZyIN88US=> M1vQZ|Q5yqCqwrC= M{[3PWROW09? NGPWW3hKSzVyPUG2N{41KM7:TR?= NXrBdmNWOjZ2NkS2OFM>
HCC827 NU\NWZJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlewOU0yPjBizszN M2GxeVQ5yqCqwrC= MWHEUXNQ NGiwdpBKSzVyPU[5MlIh|ryP MYeyOlQ3PDZ2Mx?=
A549 M3;YbWFxd3C2b4Ppd{BCe3OjeR?= NX3HSmlxQDBiwsXN NVLiRnE4PDkEoHlCpC=> NFfLWXNFVVOR MXHpcoR2[2W|IHHwc5B1d3Orcx?= MkfHNlY1PjR4NEO=
HCC827 NY\4ToZuSXCxcITvd4l{KEG|c3H5 M2jrbFgxKML3TR?= M4jyTVQ5yqCqwrC= Mly4SG1UVw>? MUHpcoR2[2W|IHHwc5B1d3Orcx?= NFjsWWQzPjR4NE[0Ny=>
SGC-7901/DDP MUDGeY5kfGmxbjDBd5NigQ>? NHO3TXUyOMLiwsXN NXXwXINsOjRiaB?= M4Hrb4lvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> NYrNcoRUOjZ2MEe2OVM>
SGC-7901  NEHocldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvSXJB7OjUEoHlCpC=> NVrNZlg2UUN3ME2xNVUvODhizszN Ml;wNlY1ODd4NUO=
SGC-7901/DDP M1TMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TkS|I1yqCqwrC= MX;JR|UxRTN3LkS1JO69VQ>? NYTqbpdyOjZ2MEe2OVM>
SGC-7901/DDP NWTCeXJxSXCxcITvd4l{KEG|c3H5 M37KZlExyqEEtV2= NHPVWXIzPCCq NHns[JdqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv M4TLZlI3PDB5NkWz
SGC-7901/DDP M13JZmZ2dmO2aX;uJGF{e2G7 M1[3SlExyqEEtV2= NVHpXYFoOjRiaB?= MULpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>? NHW1d5czPjRyN{[1Ny=>
SGC-7901/DDP Ml2wSpVv[3Srb36gRZN{[Xl? MVKxNOKhyrWP M{fyU|I1KGh? M3XvVoNifXOnczDhJI1iemunZDDk[YNz\WG|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=> NYS1dGVtOjZ2MEe2OVM>
H357 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonzO{42NzFyIN88US=> NEHUZo41QCCq M{X0PWROW09? MmL2bY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> M3HKWlI3ODB7OEe0
TAF M4K3UmZ2dmO2aX;uJGF{e2G7 MkHlNVDDqML3TR?= MlHPO{Bl NUnqS2Zs[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= MYOyOVk5PzF{Nx?=
TAF M3fq[GZ2dmO2aX;uJGF{e2G7 MVKxNOKhyrWP MoS5N|AuOTJyIH3pci=> MYXwc49zdHliYX\m[YN1eyCmQXv0JJBpd3OyaH;yfYxifGmxbjDjc45{\XG3ZX70JJRwKEWJRjDzbYdv[Wyrbne= NFzoPFgzPTl6N{GyOy=>
TAF NFLxWnBHfW6ldHnvckBCe3OjeR?= NWD1d3NjOTEEoNM1US=> MXm0PEBp NGPQRYpqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MVyyOVk5PzF{Nx?=
PANC-1 NFvIUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2yNE83OC9zMECg{txO MlGwNlQwPDhxN{KgbC=> NIHQPHFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mk\VNlU6PzNyNkK=
PANC-1 MVTGeY5kfGmxbjDBd5NigQ>? MkjUNlAwPjBxMUCwJO69VQ>? NYjaOGRDOjRiaB?= MX;heJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> NGLROnkzPTl5M{C2Ni=>
HeLa  NVX5c2M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP2NlDDqM7:TdMg MY[yOOKhcA>? MkX1[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NITvdW4zPTd5MESyNy=>
SACC-83 NHfibYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon2NlDDqM7:TdMg NVj3PXc1OjUEoHi= MVLlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M1vpPVI2PzdyNEKz
HeLa  NIC2e2dCeG:ydH;zbZMhSXO|YYm= Mn3ENlDDqM7:TdMg MnHWNlTDqGh? M{[1UYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M{jnWFI2PzdyNEKz
SACC-83 Mn\2RZBweHSxc3nzJGF{e2G7 MlyxNlDDqM7:TdMg NIS0R24zPMLiaB?= Mnny[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> M1TPSFI2PzdyNEKz
HeLa  NHHTSFdHfW6ldHnvckBCe3OjeR?= MVSyNE81OC96MDFOwG0> NUKwOGR[OjUEoHi= Mnv2eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> M3i4[lI2PzdyNEKz
SACC-83 M2Pz[mZ2dmO2aX;uJGF{e2G7 M1HpbVIxNzRyL{iwJO69VQ>? MWSyOOKhcA>? MVH1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NEfaOZYzPTd5MESyNy=>
HLCZ01 NEWxUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPrNQKBmzZywrFCuW0> NY\tdnFKPDhiaB?= NYLUToxNTE2VTx?= NFzYfmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NY\tU5lIOjV5MkS4PVk>
HLCZ01 MWPGeY5kfGmxbjDBd5NigQ>? NYHEOIc5PDEEoN88US=> NUjkSphPOjRiaB?= M4OwNWROW09? M3WxV4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NEPXS|czPTd{NEi5PS=>
HLCZ01 M1H0N2Fxd3C2b4Ppd{BCe3OjeR?= NW\KXVJnPDEEoN88US=> NYfG[HQyOjRiaB?= NFr4O2JFVVOR MX;lcohidmOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MkfhNlU4OjR6OUm=
HLCZ01 M2DCU2Z2dmO2aX;uJGF{e2G7 NV\yVnVXPDEEoN88US=> Mk[zNlQhcA>? M2HuR2ROW09? MlTNbY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x M{TZSlI2PzJ2OEm5
MGC803 NETMOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMVYxKM7:TR?= NHXoTIs4OiCq NEfRfYhKSzVyPUS3MlI26oDLwsJihKk3NjR|IN88US=> M{Pa[lI2PzBzM{e4
SGC7901 M{G4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSVGg1OC14MDFOwG0> MmTWO|IhcA>? MWHJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= M2rSSVI2PzBzM{e4
MGC803 M3HPO2Z2dmO2aX;uJGF{e2G7 NGLEZ201OMLizszN NUjaUFJRQC9zNj:yOEBp NHTz[oN2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> MXSyOVcxOTN5OB?=
SGC7901 MoOwSpVv[3Srb36gRZN{[Xl? NULGXYluPDEEoN88US=> MXe4M|E3NzJ2IHi= NXO5V4c3fXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NVHPenIyOjV5MEGzO|g>
MCF-7  MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[2NU8yOCEQvF2= NYr0T5hSPzJiaB?= NGKzPVBFVVOR NGj5Z4tmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= M1Th[|I2PjZ5NUGw
MDA-MB-231  M33aTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CwNVEwOTBizszN MVG3NkBp NYHn[lA1TE2VTx?= M1KxOYVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w M3\E[VI2PjZ5NUGw
MDA-MB-231 NGjib4pHfW6ldHnvckBCe3OjeR?= MX2wMVQxKML3TR?= NGXIVFk1NTJ2IHi= NXLTTnpjcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFnUXoIzPTV6N{OyPS=>
MCF-7 NH76SGpHfW6ldHnvckBCe3OjeR?= NXHNbWNyOC12MDFCuW0> NVL5VXZCPC1{NDDo MorN[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? NHX5VYwzPTV6N{OyPS=>
MCF7-MX  MlPJSpVv[3Srb36gRZN{[Xl? M4nmbFAuPDBiwsXN NFzYVW81NTJ2IHi= M{HQeYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? Mnq1NlU2QDd|Mkm=
MDA-MB-231 NFr0VWtHfW6ldHnvckBCe3OjeR?= NGDlT4UxNTRyINM1US=> M2jBclQuOjRiaB?= MUDzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB? MX2yOVU5PzN{OR?=
A2780 Mn33SpVv[3Srb36gRZN{[Xl? NXPUTVZkPS9zMD:xOUDPxE1? MX[0PEBp MnzS[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mnj0NlU1OjR6OUi=
SKOV3  NWC4UGZ2TnWwY4Tpc44hSXO|YYm= MXu1M|ExNzF3IN88US=> MV60PEBp MYrk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVH0cJBNOjV2MkS4PVg>
A2780 M1HlbWZ2dmO2aX;uJGF{e2G7 M4myVFUwOTBxMUWg{txO MWK0PEBp MVvlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv NF:4OZozPTR{NEi5PC=>
SKOV3  NVnzXlQ6TnWwY4Tpc44hSXO|YYm= MnPPOU8yOC9zNTFOwG0> NFzydYk1QCCq NX7pNG1S\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= Mn;HNlU1OjR6OUi=
A2780 MXrGeY5kfGmxbjDBd5NigQ>? M3XWbFUwOTBxMUWg{txO Ml7NOFghcA>? MlWy[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw M1LRPFI2PDJ2OEm4
SKOV3  NGrUTGhHfW6ldHnvckBCe3OjeR?= MlLNOU8yOC9zNTFOwG0> NF7I[os1QCCq M{OySIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= NXXNU2Q3OjV2MkS4PVg>
A2780 NFTyd|NHfW6ldHnvckBCe3OjeR?= MoqxOU8yOC9zNTFOwG0> NEHnUlQyKGh? NIH3U49qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXWyOVQzPDh7OB?=
SKOV3  MlSxSpVv[3Srb36gRZN{[Xl? MX61M|ExNzF3IN88US=> MoS2NUBp NYLIdGVEcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX2yOVQzPDh7OB?=
HCT-15 NYLoO3pFTnWwY4Tpc44hSXO|YYm= Mli3NVAuPTBizszN NF76W3U3NTN4IHi= MnvtbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NF7FenkzPTJzOECyPC=>
HT-29  NYTlepRsTnWwY4Tpc44hSXO|YYm= NInRPGkyOC13MDFOwG0> MlW4Ok0{PiCq MmfKbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NFPBNXYzPTJzOECyPC=>
HSC3  MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHjFZ2kx6oDVNECg{txO NHXlVnI1QCCq MWjJR|UxRTJ3LkZCtVEvPzhyIN88US=> NFPRcmYzPTF7OEe4PS=>
HSC3  M{DJfWFxd3C2b4Ppd{BCe3OjeR?= M{TGdFI2KM7:TR?= MoLmOFghcA>? M1[zeolv\HWlZYOgZZBweHSxc3nz M3zDSlI2OTl6N{i5
HSC3  NX;Ed2p4TnWwY4Tpc44hSXO|YYm= NYH2bYdpOjVizszN NUHRRnZ4PDhiaB?= M1fkfIV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? NFfTXGMzPTF7OEe4PS=>
HSC3  MVLGeY5kfGmxbjDBd5NigQ>? MWOyOUDPxE1? M4T6blQ5KGh? MYrpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NWrGT4NJOjVzOUi3PFk>
HSC3  NFfB[WJHfW6ldHnvckBCe3OjeR?= MlfLNlUh|ryP NVHybZk5PzJiaB?= NUXVU5Qz\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh NFHzeXEzPTF7OEe4PS=>
201T  M1jlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDibpR[PzJiaB?= NFvEblZFVVOR MV7JR|UxRTR6Lk[gxtVO NXzaeVZ[OjVyNUe5OFE>
273T NV3CbGplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS0SWk{PzJiaB?= MmT6SG1UVw>? Mm\zTWM2OD16MD61JOK2VQ>? MVqyOVA2Pzl2MR?=
Hep-2 NHL2UZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrkOWM{OC93MD:xNFAh|ryP M1j0SVEzNzJ2L{O2M|Q5KGh? NVHJd3VRTE2VTx?= M4HNdolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFy5bJkzPDl7OEW2OC=>
Hep-2 NUe4cXRDSXCxcITvd4l{KEG|c3H5 NXW0U5JHPTBizszN NEDtOlExNTR6IHi= MYnEUXNQ MXfpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NEj3dFEzPDl7OEW2OC=>
Hep-2 M1XrXWZ2dmO2aX;uJGF{e2G7 MmPpOVAh|ryP NEHwPG0xNTR6IHi= NULETZdTTE2VTx?= NV\hO4JnemWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= NEO2cWIzPDl7OEW2OC=>
Hep-2 M2j6dGZ2dmO2aX;uJGF{e2G7 M4PZbFUxKM7:TR?= MVmwMVQ5KGh? NUf4e3M4TE2VTx?= NXj2V|g5\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? M3Lrb|I1QTl6NU[0
SGC-7901 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxNE82OC9zMECg{txO MXiyOE81QC95MjDo M3K3NWROW09? MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWnwd4p2OjR7OUK5OVg>
MKN-45 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xNE82OC9zMECg{txO M13ne|I1NzR6L{eyJIg> M{LSPWROW09? NXLsenl6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MVeyOFk6Ojl3OB?=
SGC-7901 MXzGeY5kfGmxbjDBd5NigQ>? NYPtbYxbOTBxNUCvNVAxKM7:TR?= NX\OemlsPDhiaB?= NUjK[5d7TE2VTx?= NWXWbGdC\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{[0WVI1QTl{OUW4
MKN-45 MWXGeY5kfGmxbjDBd5NigQ>? M{LE[FExNzVyL{GwNEDPxE1? MX20PEBp M{XnS2ROW09? M1rxfYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NG\YPFUzPDl7Mkm1PC=>
C666-1 NFP1[4dEgXSxdH;4bYNqfHliQYPzZZk> NInTOG8zOC16MDFOwG0> Mn7GNlQhcA>? Mki4[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MVOyOFg2PDh|OB?=
CNE-1 MV7DfZRwfG:6aXPpeJkhSXO|YYm= M3fG[lIxNThyIN88US=> NXTkWY1wOjRiaB?= NGn5WlBl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh NX\ydYpHOjR6NUS4N|g>
CNE-2 NW\HfYJPS3m2b4TvfIlkcXS7IFHzd4F6 MonDNlAuQDBizszN NGLw[JMzPCCq NU\GXpc3\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NYnRUlhxOjR6NUS4N|g>
C666-1 M4f1NmN6fG:2b4jpZ4l1gSCDc4PhfS=> MYq2NEDPxE1? Mny1O{Bl M17TS4VvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NW\kcmFYOjR6NUS4N|g>
CNE-1 NYnjeYdwS3m2b4TvfIlkcXS7IFHzd4F6 MkL4OlAh|ryP Mmn2O{Bl Mk\F[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= NVexTHpxOjR6NUS4N|g>
SNU-1041 NFzRSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOwMVQxKM7:TR?= MXG0PEBp NF\OWlJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVjoT3EyOjR4OUK3NFM>
SNU-1041 M3jydWZ2dmO2aX;uJGF{e2G7 NVi2[4FyOjBxM{Cg{txO NVfs[4ZmPCCq NY\SUFRGcW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB? MkD3NlQ3QTJ5MEO=
SNU-1041 M4HZWmZ2dmO2aX;uJGF{e2G7 NWfLU5hQOC12MDFOwG0> NFG4WoU1KGh? Mnr5eZAuemWpdXzheIV{KEOKT2FCpIFnfGW{IITy[YF1dWWwdDD3bZRpKGirZ3igZ49v[2WwdILheIlwdnN? MlmwNlQ3QTJ5MEO=
SGC-7901 M2rWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXUboJDPTBvMUK1JO69VQ>? M175eFI1NzR6L{eyJIg> NWDOSIh{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MX[yOFY4PjN7NB?=
SGC-7901 MXvBdI9xfG:|aYOgRZN{[Xl? M17zc|ExOCEQvF2= NGrldI04OiCq NHXHOINqdmS3Y3XzJIFxd3C2b4Ppdy=> MoHKNlQ3PzZ|OUS=
SGC-7901 NH;JNYZHfW6ldHnvckBCe3OjeR?= MXW3OU8yODBxMUK1JO69VQ>? NIT2XHkzPC92OD:3NkBp M1P5XYlv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy MkXaNlQ3PzZ|OUS=
LMeC  MoLnSpVv[3Srb36gRZN{[Xl? MWiyNE82OCEQvF2= MYC0PEBp MmHM[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IIDyc5RmcW5? MmPDNlQ3PTZ5NE[=
CMeC-1 M4[2VmNmdGxiVnnhZoltcXS7IFHzd4F6 NGjXdVYzOC93MDFOwG0> M3X1[VQ5KGh? MVjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4nW[VI1PjV4N{S2
LMeC NVzaWnRPS2WubDDWbYFjcWyrdImgRZN{[Xl? MoXINlAwPTBizszN NVrHcGJYPDhiaB?= MXvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{PTdFI1PjV4N{S2
CMeC-1 MUnGeY5kfGmxbjDBd5NigQ>? MkLINlAwPTBizszN NIHxR4s1QCCq M{jneIlv\HWlZYOgS|EuWyCjcoLld5Q> MojVNlQ3PTZ5NE[=
LMeC MW\GeY5kfGmxbjDBd5NigQ>? MkLRNlAwPTBizszN NXPNbpdQPDhiaB?= M1PVfYlv\HWlZYOgS|EuWyCjcoLld5Q> MWOyOFY2Pjd2Nh?=
CMeC-1 M37wdGZ2dmO2aX;uJGF{e2G7 NVXqPFROOjBxNUCg{txO NXPvWndxPDhiaB?= M{L0cYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{T0NlI1PjV4N{S2
LMeC NVHK[ZVMTnWwY4Tpc44hSXO|YYm= NF7GW4MzOC93MDFOwG0> MnzqOFghcA>? NFP4VYll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnSwNlQ3PTZ5NE[=
CMeC-1 NWq1XFVSTnWwY4Tpc44hSXO|YYm= M2L3eVIxNzVyIN88US=> NIP5U5g1QCCq NH3UUm5qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MXyyOFY2Pjd2Nh?=
LMeC NVqx[41ZTnWwY4Tpc44hSXO|YYm= M1u0fVIxNzVyIN88US=> NVPhbWlzPDhiaB?= NXe2RWVYcW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? NV7MNlY1OjR4NU[3OFY>
OVCAR-3 MonuR4VtdCCYaXHibYxqfHliQYPzZZk> MkXwNVAhyrWP NWTLeod{OSCq MYjlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg NV;s[4V1OjR3MkCyNlc>
OVCAR-3 NEH5U5hCeG:ydH;zbZMhSXO|YYm= NHfFbWoyOCEEtV2= M1HnZlEhcA>? MWjwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MWWyOFUzODJ{Nx?=
OVCAR-3 NWPPUpVXTnWwY4Tpc44hSXO|YYm= M{TZO|ExKML3TR?= NUPQNIxKOSCq M2XGTYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg MmfzNlQ2OjB{Mke=
OVCAR-3 NHf6NJpHfW6ldHnvckBCe3OjeR?= NYPIZXNUOTBiwsXN NFzSdFcyKGh? M1TzWYRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> NHT2TW4zPDV{MEKyOy=>
OVCAR-3 NE[4enNHfW6ldHnvckBCe3OjeR?= M2[xPFExKML3TR?= MYSxJIg> NVTYXpdMcW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? MVKyOFUzODJ{Nx?=
CF33 M4q5bGZ2dmO2aX;uJGF{e2G7 NGHBU3QyODBizszN NHHXW4QzPCCq MmHLbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25? MUOyOFUxOzd6Mh?=
CF33 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHDNVAuOTByIN88US=> M3TxRVAuPCCm MXzpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYOyOFUxOzd6Mh?=
CF33 MX;GeY5kfGmxbjDBd5NigQ>? MX:xNE0yODBizszN MWC0MVI1KGh? MVPk[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> NFnTZoYzPDVyM{e4Ni=>
LNCaP MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzpNk82NzFyIN88US=> MmjJPVYhcA>? NULFU3NjcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MY[yOFI6Pjl5OB?=
LNCaP MmDHRZBweHSxc3nzJGF{e2G7 M1zkUFIwPS9zMDFOwG0> NU\5XZluQTZiaB?= Mk\4bY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= Mn;DNlQzQTZ7N{i=
PC-3  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHMdXkxNTVyIN88US=> NIDRfpY1QOLCiXi= NYjlUXZ3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlfkNlQyOjd6OEK=
PC-3  MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlHZNE0yODBizszN M3nEVlczKGh? MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NYntO4pwOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4
NCT02827487 Not yet recruiting Pain Cairo University July 2017 Phase 4
NCT02770378 Not yet recruiting Glioblastoma University of Ulm|Reliable Cancer Therapies|Anticancer Fund, Belgium August 2016 Phase 1
NCT02703363 Not yet recruiting Depression|Bipolar Disorder|Bipolar Depression|Mood Disorders Pakistan Institute of Learning and Living|Dow University of Health Sciences|Abbasi Shaheed Hospital|Rawalpindi Medical College, Pakistan|University of Manchester|Stanley Medical Research Institute August 2016 Phase 3
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University July 2016 Phase 2
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID